19 March 2019
Visiongain has published a new pharma report Global Anaesthesia Drugs Market Report : Local Anaesthesia, General Anaesthesia, Inhalation Anaesthesia, Intravenous Anaesthesia, Topical Anaesthesia, Benzocaine, Bupivacaine, Chloroprocaine, Lidocaine, Prilocaine, Ropivacaine, Desflurane, Dexmedetomidine, Midazolam, Propofol, Remifentanil, Sevoflurane and Others.
The Global Anaesthesia Drugs Market is estimated to grow at a CAGR of 3.9% from 2019 to 2024, dominated by the local anaesthesia submarket.
The global anaesthesia drugs market is projected to grow at lucrative rate during the forecast period owing to a rising number of surgical procedures globally, developing healthcare infrastructure in emerging economies, and growing number of geriatric population.
This report profiled the selected companies: AbbVie, AstraZeneca, Aurobindo Pharma, Baxter International, Inc., Fresenius Kabi, Hameln Pharmaceuticals and others.
The lead analyst commented that "The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons. However, inhalation route of administration is projected to grow at the fastest rate owing to its growing application during the most critical as well as simple surgeries as the depth of inhaled anaesthesia is easy to control and advent from anaesthetic is rapid with minimum deleterious after effects."
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.
15 September 2022
The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.